ZUG, SWITZERLAND--(Business Wire / Korea Newswire)--Galderma (SWX:GALD) announced today the launch of its hyaluronic acid injectable filler, Restylane® VOLYME™ in China. The company is also introducing its complementary Shape Up Holistic Individualized Treatment (HIT™) in the country, which addresses aging concerns caused by loss of structural support in the mid-face. The availability of these targeted solutions for the mid-face region is demonstrative of Galderma’s commitment to meeting patient and injector needs in China. In the past decade, the growth of China’s aesthetics medicine market has outpaced the global market; with relatively low market penetration, there remains significant potential for future growth.[1]

Developed using Galderma’s proprietary OBT™* gel technology, Restylane® VOLYME™ is indicated for the correction of mid-face volume deficit and/or mid-face contour deficiency through injections into the subcutaneous to supraperiosteal layers of the skin.[2-3] Hyaluronic acid fillers are often patients’ first choice for mid-face augmentation and have been shown to deliver high patient satisfaction and long-lasting effects.[4] In China, hyaluronic acid fillers are among the top 10 most-sold aesthetics products.[1]

“We are delighted to deliver Galderma’s innovative aesthetics solutions in China with the support of our research and development teams, as well as local partners and regulatory authorities. As the Chinese market continues to expand, we look forward to working closely with all stakeholders to deliver our full, premium range of aesthetics products to meet the varied and individual needs of patients and injectors.”
GERRY MUHLE HEAD OF GLOBAL PRODUCT STRATEGY GALDERMA

Developed with a global community of injectors, the Shape Up HIT™ is the latest of Galderma’s HITs™ to be introduced in China, designed to create a common language to facilitate a two-way dialogue between patient and practitioner to align on patient priorities and keep satisfaction at the forefront.

“Aesthetic plastic surgery is an artistic creation under medical constraints, embodying a holistic and individualized approach. Facial expressions are controlled by 42 muscles which convey emotions such as joy, anger, sorrow, and happiness. These muscles are also involved in language, chewing, and other activities. The appearance of the mid-face is crucial in interpersonal communication. Together, Restylane® VOLYME™ and the Shape Up HIT™ enable patients to maintain their natural facial expressions while also supporting injectors to deliver a youthful and long-lasting aesthetic effect.”
PROFESSOR HAIYAN CUI DIRECTOR OF THE INSTITUTE OF AESTHETIC PLASTIC SURGERY AND MEDICINE TONGJI UNIVERSITY DIRECTOR OF THE PLASTIC & COSMETIC SURGERY DEPARTMENT TONGJI HOSPITAL OF TONGJI UNIVERSITY

HIT™ is an individualized treatment approach which enables injectors to leverage their expertise with the renowned Galderma Restylane® portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction. The Balanced Profile HIT™ was Galderma’s first HIT™ to be introduced in China in 2023, providing a framework for practitioners to conduct a full objective facial assessment for the patient and help bring balance to their profile. HIT™ naturally springboards from Galderma’s AART™ (Assessment, Anatomy, Range, Treatment) methodology for a new generation of individualized aesthetics.

Restylane® is the largest and most diverse range of individually engineered hyaluronic acid fillers on the market, approved in more than 80 countries and regions, and with over 65 million treatments administered worldwide.[5-8]

About Galderma

Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ - the skin - meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com

Notes and references:

* Optimal Balance Technology - OBT

[1] Deloitte. China Aesthetic Medicine Outlook Report. Accessed May 2024. Available online.
[2] Talarico S et al. High patient satisfaction of a hyaluronic acid filler producing enduring full-facial volume restoration: An 18-month open multicenter study. J Dermatol Surg. 2015; 41: 1361-1369.
[3] Galderma. Restylane Instructions for Use.
[4] Trinh LN & Gupta A. Hyaluronic acid fillers for midface augmentation: A systematic review. Facial Plast Surg. 2021; 37(5): 576-584.
[5] Öhrlund A. New method to study the balance of firmness and flexibility for HA fillers. Poster presented at AMWC 2019.
[6] Galderma. Data on file. MA-57232.
[7] Galderma. Data on file. MA-33939.
[8] Galderma. Data on file. QMS-3637.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522425104/en/

Website: http://www.galderma.com Contact Galderma
Christian Marcoux, M.Sc.
Chief Communications Officer
+41 76 315 26 50
[email protected]

Sébastien Cros
Corporate Communications Director
+41 79 529 59 85
[email protected]

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
+41 21 642 78 12
[email protected]

Jessica Cohen
Investor Relations and Strategy Director
+41 21 642 76 43
[email protected]
This news is a press release provided by Galderma. Korea Newswire follows these editorial guidelines. Galderma News ReleasesSubscribeRSS Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries Galderma today announced that it has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia, Singapore, Switzerland, and the United Kingdom, whose regulatory a... 5월 7일 14:35 Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024. · Record net sales of 1.071 billion USD in the first quarter of 2024, surpassing for the first time the 1 billion USD mark for the first three mo... 4월 24일 14:34 ... More  More News Health Pharmaceutical Life Style Beauty New Product Overseas Galderma All News Releases 